OptiBiotix Health (LSE:OPTI) has announced a major enhancement to its SweetBiotix® manufacturing process, unveiling a new enzymatic technology that boosts production yield and purity while lowering overall costs. The improvement also refines the taste profile of the natural, high-fiber, low-calorie sweeteners, which are designed as healthier alternatives to both sugar and artificial sweeteners. Management expects the innovation to reinforce SweetBiotix’s competitive position by directly addressing consumer and industry concerns around sugar substitutes. The development could also broaden partnership opportunities with sugar producers and is anticipated to lift investor confidence as commercial potential expands.
More about OptiBiotix Health
OptiBiotix Health plc is a life sciences company developing microbiome-modulating products aimed at preventing and managing disease. Its portfolio includes prebiotic ingredients such as SlimBiome®, WellBiome®, SweetBiotix®, and Microbiome Modulators. The company also maintains interests in skincare through SkinBioTherapeutics plc and probiotics via ProBiotix Health plc, reflecting rising global demand for science-driven health and wellness solutions.
Leave a Reply